![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Domainex will provide its expertise in medicinal and computational chemistry, screening, structural biology and ADME/PK to advance APEIRON’s promising Cbl-b targeting compound series APN431 towards pre-clinical development.
Lead Product(s): APN431
Therapeutic Area: Oncology Product Name: APN431
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Apeiron Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 09, 2020
Details:
The partnership aims at discovering a drug that inhibits the protease target, activated Factor XII.
Lead Product(s): Undisclosed
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: LUNAC Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 25, 2020